Owner Scorecard


← All companies ← ABSI Manual ABTC → ← ABBV Pharmaceuticals ABUS →

ABT, Abbott Laboratories

Pharmaceuticals consumer brand

Abbott sells a broad, mixed line of healthcare products: medical devices, diagnostic tests and the instruments that run them, nutrition for infants and adults, and branded generic medicines marketed mostly outside the United States in emerging markets. The buyers are hospitals, labs, doctors, pharmacies, and ordinary people around the world. It makes its money the way a brand maker does — selling many small, repeat-purchase items under trusted names, often with a device or analyzer that pulls a stream of consumables behind it.

On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market.

Certain products are co-marketed or co-promoted with, or licensed from, other companies.

Latest annual: FY2025 10-K
ABT · Abbott Laboratories
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$44.3B
+5.7% YoY · 5% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $45.1B 5-yr avg $42.6B
Gross margin 56% 5-yr avg 56%
Operating margin 17.1% 5-yr avg 17.9%
ROIC 7% 5-yr avg 14%
Owner-earnings margin 18% 5-yr avg 18%
Free cash flow margin 16% 5-yr avg 16%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What moves the needle
This is four businesses under one roof — devices, diagnostics, nutrition, branded generics — and the question is whether they are a franchise or a fair business dressed up by scale. The test is pricing power and repeat custom: a monitor or a lab analyzer placed with a customer should sell its own consumables for years, and a trusted formula or nutrition name should hold its shelf; look to the gross margin and return on capital below for whether that razor-and-blade economics actually shows. The bad case is plain in the filing's own emphasis — every market here is competitive and heavily regulated worldwide, a product can be sued (a state jury handed down a large award), and a generics line competes mainly on price. The record below says whether the brand earns its keep or merely funds a steady, ordinary return.
Is it a good business?
Return on capital has sat near the cost of capital (median 11%). By owner earnings: roughly 17% of revenue reaches owners as cash, consistently. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Drafted from the company's filings and reviewed by hand; every number is shown in full in the sections below.

Where the money comes from

read the 10-K →

61% of revenue comes from outside the United States.

Revenue by geography, FY2025
  • United States39%$17.1B
  • All Other Countries36%$16.0B
  • Germany6%$2.8B
  • China4%$1.9B
  • Switzerland4%$1.9B
  • India4%$1.9B
  • Other6%$2.8B

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$20.9B$27.4B$30.6B$31.9B$34.6B$43.1B$43.7B$40.1B$42.0B$44.3B$45.1BRevenueRevenue
56%55%58%59%57%57%56%55%55%56%56%Gross marginGross mgn
32%34%32%31%28%26%26%27%28%28%29%SG&A / revenueSG&A/rev
7%8%8%8%7%6%7%7%7%7%7%R&D / revenueR&D/rev
$3.0B$1.6B$3.6B$4.5B$5.4B$8.4B$8.4B$6.5B$6.8B$8.1B$7.7BOperating incomeOp. inc.
14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%17.1%Operating marginOp. mgn
$1.4B$477M$2.4B$3.7B$4.5B$7.1B$6.9B$5.7B$13.4B$6.5B$6.3BNet incomeNet inc.
20%19%10%10%14%17%14%23%23%Effective tax rateTax rate
Cash flow & returns
$3.2B$5.6B$6.3B$6.1B$7.9B$10.5B$9.6B$7.3B$8.6B$9.6B$9.5BOperating cash flowOp. cash
$803M$1.0B$1.1B$1.1B$1.2B$1.5B$1.3B$1.3B$1.3B$1.4B$1.5BDepreciationDeprec.
$690M$3.6B$2.4B$852M$1.7B$1.3B$709M($383M)($6.9B)$944M$1.0BWorking capital & otherWC & other
$1.1B$1.1B$1.4B$1.6B$2.2B$1.9B$1.8B$2.2B$2.2B$2.2B$2.1BCapexCapex
5.4%4.1%4.6%5.1%6.3%4.4%4.1%5.5%5.3%4.9%4.6%Capex / revenueCapex/rev
$2.4B$4.4B$5.2B$5.1B$6.7B$9.0B$8.3B$6.0B$7.2B$8.1B$8.0BOwner earningsOwner earn.
11.5%16.2%17.0%15.9%19.4%21.0%19.1%14.9%17.2%18.3%17.7%Owner earnings marginOE mgn
$2.1B$4.4B$4.9B$4.5B$5.7B$8.6B$7.8B$5.1B$6.4B$7.4B$7.4BFree cash flowFCF
10.0%16.2%16.0%14.1%16.5%20.1%17.9%12.6%15.1%16.7%16.3%Free cash flow marginFCF mgn
$80M$17.2B$17.2BAcquisitionsAcquis.
$1.5B$1.8B$2.0B$2.3B$2.6B$3.2B$3.3B$3.6B$3.8B$4.1B$4.2BDividends paidDiv. paid
$522M$117M$238M$718M$403M$2.3B$3.8B$1.2B$1.3B$893MBuybacksBuybacks
11%2%6%9%11%16%16%12%13%11%7%ROICROIC
7%2%8%12%14%20%19%15%28%13%12%Return on equityROE
−1%−4%1%5%6%11%10%6%20%5%4%Retained to equityRetained/eq
Balance sheet
$18.8B$9.6B$4.1B$4.1B$7.1B$10.2B$10.2B$7.3B$8.0B$8.9B$7.3BCash & investmentsCash+inv
$3.2B$5.2B$5.2B$5.4B$6.4B$6.5B$6.2B$6.6B$6.9B$7.9B$8.2BReceivablesReceiv.
$2.4B$3.6B$3.8B$4.3B$5.0B$5.2B$6.2B$6.6B$6.2B$6.5B$7.0BInventoryInvent.
$1.2B$2.4B$3.0B$3.3B$3.9B$4.4B$4.6B$4.3B$4.2B$4.2B$4.7BAccounts payablePayables
$4.5B$6.4B$6.0B$6.5B$7.5B$7.2B$7.8B$8.8B$8.9B$10.2B$10.5BOperating working capitalOper. WC
$26.8B$20.1B$14.6B$15.7B$20.4B$24.2B$25.2B$22.7B$23.7B$26.0B$25.5BCurrent assetsCur. assets
$6.7B$8.9B$9.0B$10.9B$11.9B$13.1B$15.5B$13.8B$14.2B$16.5B$18.4BCurrent liabilitiesCur. liab.
4.0×2.3×1.6×1.4×1.7×1.8×1.6×1.6×1.7×1.6×1.4×Current ratioCurr. ratio
$7.7B$24.0B$23.3B$23.2B$23.7B$23.2B$22.8B$23.7B$23.1B$24.0B$35.2BGoodwillGoodwill
$52.7B$76.3B$67.2B$67.9B$72.5B$75.2B$74.4B$73.2B$81.4B$86.7B$110.4BTotal assetsAssets
$20.7B$27.7B$19.4B$17.9B$18.5B$18.1B$16.8B$14.7B$14.1B$12.9B$34.0BTotal debtDebt
$1.9B$18.1B$15.3B$13.8B$11.4B$7.8B$6.6B$7.4B$6.2B$4.0B$26.8BNet debt / (cash)Net debt
7.0×1.7×4.4×6.8×9.8×15.8×15.0×10.2×12.2×16.3×14.4×Interest coverageInt. cov.
$20.5B$30.9B$30.5B$31.1B$32.8B$35.8B$36.7B$38.6B$47.7B$52.1B$52.1BShareholders’ equityEquity
1.5%1.5%1.6%1.6%1.6%1.5%1.6%1.6%1.6%1.5%1.5%Stock comp / revenueSBC/rev
Per share
1.48B1.75B1.77B1.78B1.79B1.79B1.76B1.75B1.75B1.75B1.75BShares out (diluted)Shares
$14.06$15.66$17.28$17.91$19.38$24.08$24.75$22.93$24.00$25.36$25.83Revenue / shareRev/sh
$0.94$0.27$1.34$2.07$2.52$3.95$3.93$3.27$7.67$3.73$3.59EPS (diluted)EPS
$1.62$2.54$2.94$2.84$3.75$5.05$4.72$3.42$4.13$4.65$4.57Owner earnings / shareOE/sh
$1.40$2.54$2.77$2.53$3.20$4.83$4.42$2.89$3.63$4.23$4.22Free cash flow / shareFCF/sh
$1.04$1.06$1.12$1.27$1.43$1.79$1.88$2.03$2.19$2.35$2.40Dividends / shareDiv/sh
$0.76$0.65$0.79$0.92$1.22$1.05$1.01$1.26$1.26$1.24$1.19Cap. spending / shareCapex/sh
$13.85$17.67$17.25$17.46$18.36$20.01$20.80$22.07$27.27$29.82$29.80Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+6.8%/yr+5.5%/yr
Owner earnings / share+12.4%/yr+4.4%/yr
EPS+16.5%/yr+8.2%/yr
Dividends / share+9.5%/yr+10.4%/yr
Capital spending / share+5.7%/yr+0.4%/yr
Book value / share+8.9%/yr+10.2%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
1.7Bpeak FY2021
ROIC
11%low FY2017
Gross margin
56%low FY2017
Net debt ÷ owner earnings
0.5×peak FY2017

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

$8.1Bowner earningsvs.$6.5Bnet incomelow FY2016

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cash

Each year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.

FY2016FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned $8.1B of owner earnings, the operating cash left after the $1.4B it takes just to hold its position. It put $737M more into growth; free cash flow, after that spending, was $7.4B.

Reported net income$6.5B
Owner earnings$8.1B · 18% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$6.5B$13.4B$5.7B$6.9B$7.1B
Depreciation & amortizationnon-cash charge added back+$1.4B+$1.3B+$1.3B+$1.3B+$1.5B
Stock-based compensationreal costnon-cash, but a real cost+$664M+$673M+$644M+$685M+$640M
Working capital & othertiming of cash in and out, other non-cash items+$944M−$6.9B−$383M+$709M+$1.3B
Cash from operations$9.6B$8.6B$7.3B$9.6B$10.5B
Maintenance capital expenditurethe spending needed just to hold position and volume−$1.4B−$1.3B−$1.3B−$1.3B−$1.5B
Owner earnings$8.1B$7.2B$6.0B$8.3B$9.0B
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$737M−$867M−$925M−$523M−$394M
Free cash flow$7.4B$6.4B$5.1B$7.8B$8.6B
Owner-earnings marginowner earnings ÷ revenue18%17%15%19%21%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $1.4B, roughly its depreciation, the rate its assets wear out). The other $737M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $664M), owner earnings is nearer $7.5B.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Comfortable
    Operating income $8.1B ÷ interest expense $493M
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • How heavy is the debt, net of cash? $4.0B · 0.5× operating profit
    Modest net debt
    Cash $8.5B + ST investments $417M − debt $12.9B
    What this means

    Netting $8.9B of cash and short-term investments against $12.9B of debt leaves $4.0B owed, about 0.5× a year's operating profit (1.6× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 65 + DIO 123 − DPO 80 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Solid through the cycle
    10-yr median, range 2%–16%; 11% latest = NOPAT $6.2B ÷ invested capital $56.5B
    Industry peers: median 19%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 11% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High through the cycle
    10-yr median margin, range 12%–21%; latest $8.1B = operating cash $9.6B − maintenance capex $1.4B
    Industry peers: median 28%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 18% of revenue this year, a 17% median across 10 years. Treating stock comp as the real expense it is (less $664M of SBC) leaves $7.5B.

  • Cash-backed
    Cash from ops $9.6B ÷ net income $6.5B
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Returns about half
    Dividends + buybacks $5.0B ÷ Owner Earnings $8.1B
    What this means

    Of $8.1B Owner Earnings, $5.0B (62%) went back to shareholders, $4.1B dividends, $893M buybacks. Net of $664M stock comp, the real buyback was about $229M. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 1.51×
    Expanding
    Capex $2.2B ÷ depreciation $1.4B
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 4 of 6 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Pass
    Revenue ≥ $2B · $44.3B
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Near
    Current ratio ≥ 2× · 1.58×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Near
    Debt ≤ working capital · $12.9B vs $9.5B WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Pass
    A profit every year (10-yr record) · no losses
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Pass
    Uninterrupted dividends · paid every year (10)
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Pass
    Earnings +33% over the record · +504%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $4.91/share (latest year $3.75), the averaged base the calculator's gate runs on, and book value is $29.93/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 10 of 10
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Return on capital ≥ 15% 2 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 11% → 17% (3-yr avg ends)

    In the filing’s words The words confirm the number: the filing says price increases held their volume, and the margin widened with them — Buffett’s strongest mark of pricing power.

    What this means

    Through the cycle the operating margin widened — about 11% early to 17% lately, median 15% — pricing power intact or improving.

  • Reinvestment, incremental ROIC 32%
    What this means

    Every extra dollar the business reinvested came back at a high incremental return — the lens GBM read for a moat that reinvests rather than merely harvests. The record and the 10-K are where you check whether the rate holds.

  • Owner earnings growth +9%/yr
    What this means

    Owner earnings grew about 9% a year over the record.

  • Worst year 2017 · 5.7% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count +1.8%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Named as a competitive risk

Its FY2025 10-K names artificial intelligence as a competitive threat.

“Further, the development of new technologies, including disruptive technologies such as artificial intelligence, healthcare products and medicines, and the development of new treatments for disease could significantly change the competitive landscape of the healthcare industry and negatively impact the demand for certa…”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$25.5B
  • Cash & short-term investments$7.3B
  • Receivables$8.2B
  • Inventory$7.0B
  • Other current assets$3.0B
Current liabilities$18.4B
  • Debt due within a year$4.4B
  • Accounts payable$4.7B
  • Other current liabilities$9.3B
Current ratio1.39×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.01×stricter: inventory excluded
Cash ratio0.40×strictest: cash alone against what's due
Working capital$7.1Bthe cushion left after near-term bills
Debt due this year vs. cash$4.4B due · $7.3B cash covered by cash on hand, no refinancing forced · both figures from the Mar 31, 2026 balance sheet
Revenue, latest quarter vs. a year ago+7.8%the freshest read on whether the business is still growing
Current ratio, recent quarters1.7× → 1.4×
Deeper floors
Tangible book value($1.0B)equity stripped of goodwill & intangibles
Debt incl. operating leases$35.3B$1.2B of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $74.6B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested$17.7B · 24%
  • Dividends$28.2B · 38%
  • Buybacks$11.5B · 15%
  • Retained (debt / cash)$17.2B · 23%
  • Returned to owners$39.7B

    64% of the owner earnings the business produced over the span, $28.2B as dividends and $11.5B as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span debt rose $13.4B and cash and short-term investments fell $11.5B.

  • Average price paid for buybacks

    Buybacks ran $11.5B over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count17.8%

    The diluted count rose from 1483M to 1747M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record$2.35/sh

    Paid in 10 of the years on record, the per-share dividend growing about 10% a year. It was never cut over the span.

  • Return on what it retained25%

    Of the earnings it kept rather than paid out ($12.4B over the span), annual owner earnings (first three years vs last three) grew $3.1B, so each retained $1 added about 0.25 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Acquisitions & goodwill

from the balance sheet & the 10-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$29.6B34% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equity46%goodwill is this share of book equity; the rest is the company’s own retained and paid-in capital
Cash spent acquiring$17.3Bover 10 years buying other businesses, against $17.7B of capital spent building

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Robert B. Ford$24.9M$43.3M$9.0B
2022Robert B. Ford$21.7M$8.0M$8.3B
2023Robert B. Ford$23.3M$20.5M$6.0B
2024Robert B. Ford$22.8M$24.8M$7.2B
2025Robert B. Ford$24.2M$26.8M$8.1B

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • CEO pay ratio166:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$664M

    The slice of the business handed to employees in shares this year, 1% of revenue, equal to 8% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Inverting the record

Invert: instead of why Abbott Laboratories is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

1 of the 5 tests turned up something to look into; the other 4 came back clean.

  • Look hereDid the share count rise anyway?17.8%

    Diluted shares grew 17.8% over 2016–2025, even as the company spent $11.5B on buybacks. The repurchases were outrun by issuance — to staff, in a raise, or in a deal — and the filing says which; owners' slice still shrank. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did debt outgrow the business?
  • Did reported profit become cash?
  • Did receivables and inventory outpace sales?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
JNJJohnson & Johnson$94.2B67%23.8%22%23%
LLYEli Lilly and Company$65.2B78%24.0%27%20%
MRKMerck & Company Inc. Common Stock (new)$65.0B70%25.9%19%21%
PFEPfizer Inc.$62.6B75%26.1%11%28%
ABBVAbbVie Inc.$61.2B70%28.0%21%38%
BMYBristol-Myers Squibb Company$48.2B72%18.9%12%28%
ABTAbbott Laboratories$44.3B56%15.8%11%17%
AMGNAmgen Inc.$36.8B76%36.1%18%35%
Group median71%24.9%18%25%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Abbott Laboratories has delivered.

$

Through the cycle, Abbott Laboratories earns about $7.6B on its 17.1% median owner-earnings margin. This year’s 18.3% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25−3%/yr
Owner-earnings growth · ’16→’25+9%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $7.4B on 1742M shares outstanding, per the 10-Q cover, as of 2026-03-31; net debt $26.8B. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($2.1B) runs well above depreciation ($1.5B), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $8.0B, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Abbott Laboratories (ABT), the owner's record," https://ownerscorecard.com/c/ABT, data as of 2026-07-09.

Manual order: ← ABSI its page in the Manual ABTC →

Industry order: ← ABBV the Pharmaceuticals chapter ABUS →